Table of Contents
Definition, Etiology, and Pathophysiology
Thrombocytopenia is a deficiency of thrombocytes in peripheral blood. Thrombocytes are functionally integrated into the hemostasis system. Thus, disorders of thrombocyte function cause pathological bleeding. In the spectrum of hemorrhagic diatheses, this type of coagulopathy is the main cause of pathological bleeding.
Like almost all bleeding disorders, the causes of thrombocytopenia can be divided into disturbed synthesis or increased peripheral turnover.
Thrombocytopenia due to synthesis disorders
Decreased thrombocytopoiesis can occur in the context of an aplastic disorder. For example, Fanconi anemia is a congenital variation. Acquired blood cell (and thus, thrombocyte) synthesis disorders include bone marrow lesions via radiation, chemicals, medications, infections (e.g., HIV), or antibodies. In addition, bone marrow lesions are possible in the context of malignant infiltration in leukemia, carcinomas, or lymphomas. Similarly, the myeloproliferative disease can likewise replace the bone marrow in the course of the respective disease.
Synthesis disorders can, however, also develop if the bone marrow is functioning properly. For example, maturation of the cells can be impaired, which occurs in cases of vitamin deficiency. In this context, vitamin B12 or folic acid deficiencies are especially important.
Thrombocytopenia due to increased peripheral turnover
The bone marrow can adequately compensate peripheral thrombocyte consumption and for long periods of time. If this consumption exceeds the synthesis ability of the bone marrow, thrombocytopenia develops. The lifespan of thrombocytes is short (about 1 week), and in the event of increased consumption, the thrombocytes are partially consumed after some hours, and the turnover experiences a fivefold increase. These numbers illustrate the high capability of the bone marrow.
Peripheral consumption can be further divided into:
Many mechanisms lead to the production of autoantibodies against thrombocytes. If thrombocytopenia is observed after a previous infection, an acute post-infectious immune thrombocytopenia is probably present. It often affects children after gastrointestinal or respiratory viral infections. In most cases, the disease is self-limiting. In such cases, aspirin must not be given! If spontaneous healing does not occur, glucocorticoids can be administered. Thrombocyte concentrations only become necessary in the event of life-threatening bleeding.
Apart from the acute form, there is also a chronic variation: chronic immune thrombocytopenic purpura (Werlhof’s disease). Here, autoantibodies are produced in the spleen. The disease is often associated with Helicobacter pylori-gastritis. Therapeutically, immunosuppressive therapy is initiated (glucocorticoids, immunoglobulins, or rituximab) besides the H. pylori eradication and careful observation. The last resort is splenectomy.
Further, it should be noted that drugs can provoke antibody production. However, a notable variation is heparin-induced thrombocytopenia (HIT), during which antibodies are produced against the heparin/platelet factor-4-complex due to heparin therapy. This syndrome is potentially life-threatening. Therapy has to be stopped or changed immediately.
Autoantibodies can also be produced in the context of several underlying diseases, e.g., systemic lupus erythematosus, rheumatoid arthritis, HIV infection, malignant lymphoma, and HELLP syndrome (hemolysis, elevated liver enzymes, and a low platelet count). It is also important to consider allo-antibody-induced thrombocytopenia after blood transfusions.
Thrombocytopenia due to enhanced thrombin activity
Enhanced thrombin activity can be observed in disseminated intravascular coagulation (DIC) and in malignant and infectious processes.
Thrombocytopenia of mechanical genesis
Implanted artificial cardiac valves can mechanically damage the thrombocytes and, thus, alter the blood count. Further, extracorporeal exchange measures like dialysis or heart-lung-machines show a similar effect.
Thrombocytopenia due to other causes
Thrombocytopenia often occurs in the context of splenomegaly. However, the spleen allows the pooling of thrombocytes and simultaneously causes increased degradation. Compared to synthesis disorders in the bone marrow, all cell lines are mostly affected. Thrombotic microangiopathy or hemolytic-uremic syndrome also leads to thrombocytopenia via the development of thrombi rich in thrombocytes with microangiopathy.
Blood testing techniques can lead to false conclusions and a wrong suspicion of thrombocytopenia. Due to EDTA-agglutinins or cold agglutinins, very low thrombocyte counts can be reported, without the patient showing clinical symptoms. Thus, another blood sample should be taken and sent to the laboratory for testing; this time, preferably in a citrate tube.
Signs and Symptoms
Clinical presentation of thrombocytopeniaClinically, thrombocytopenia becomes relevant at values of < 80,000/µL since increased bleeding tendency has to be assumed at this level, as long as no functional disorder of the thrombocytes (thrombocytopathy) is present. The classic characteristic of thrombocytic bleedings are petechiae, which develop at thrombocyte counts of under < 50,000/µL. Depending on the underlying disease, additional symptoms can manifest and are heterogeneous in nature. It is important to identify the exact cause of the clinical manifestation of a suspected underlying disease in the event of detected thrombocytopenia.
Thrombocytopenia needs extensive anamnesis
The diagnosis of thrombocytopenia is made if < 140,000 thrombocytes per µL of blood are present. Diagnostically, it is important to conduct an extensive and targeted review, which narrows down the differential diagnoses. Additionally, the physician should consider the existence of an underlying disease. In the case of blood diseases, all cell lines have to be critically determined and evaluated!
Bone marrow analysis in thrombocytopenia
Diagnostics can include bone marrow analysis. If the megakaryocyte count is decreased, a synthesis disorder is present. In the event of an increased megakaryocyte count, a maturation or turnover disorder exists. Further, bone marrow analysis allows direct conclusions regarding primary or secondary bone marrow malignancies.
Therapy depends on the extent and kind of thrombocytopenia. A pre-existing disease should be treated where possible. Drugs that exacerbate the disease should be immediately discontinued.
Symptomatically, thrombocytopenia is treated with transfusions of thrombocyte concentrates. In addition to different interventional or surgical measures, the thrombocyte count should be raised to certain values to minimize the risk of severe blood loss. As a benchmark, a target thrombocyte count of > 50,000/µL is reasonable. Thrombocyte concentrates are either acquired from freshly taken whole-blood units or via mechanical thrombocyte apheresis.
If no significant increase in thrombocyte count occurs after the administration of thrombocyte concentrates, the cause should be identified. The following causes should be considered:
- Splenomegaly, fever, sepsis, DIC, infections, or bleedings: The new thrombocytes are directly consumed.
- Immunological factors: Antibodies are eliminating the new thrombocytes.
More Information about Thrombocytopathies
Thrombocytic bleeding can also occur at normal thrombocyte values. In such a case, one should consider thrombocyte function disorders, which can occur in the context of different inherited diseases of metabolism or antiplatelet drug therapy.